Johnson & Johnson dividend track and sector role, health care stock in steady focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 13:33.

Johnson & Johnson (US4781601046) remains one of the largest health care stocks in the S&P 500, backed by a long record of dividend payments and a diversified portfolio. The company is a core holding for many income-focused investors on the New York Stock Exchange, with valuation and litigation risks a recurring topic in analyst research.

How analysts view Johnson & Johnson

Johnson & Johnson is covered by a broad analyst community on Wall Street, with most major houses including the stock in their health care or dividend strategies. Consensus data compiled by MarketScreener in late June 2026 shows a mix of Buy, Hold and Sell ratings, resulting in a neutral overall stance on the shares, with the average 12-month price target only moderately above the recent market price. MarketScreener consensus data on Johnson & Johnson

For many institutional investors, the company is primarily viewed as a high-quality dividend payer, supported by its diversified business and strong balance sheet. Johnson & Johnson has raised its dividend for decades, making it a classic dividend aristocrat in the United States and a building block in defensive portfolios, especially in times of elevated volatility in cyclical sectors such as technology and industrials.

Dividends, litigation and peer comparison

In its most recent shareholder communication, Johnson & Johnson confirmed its commitment to a reliable dividend policy, building on a track record of annual dividend increases stretching over half a century and underpinned by solid free cash flow. The company positions itself as a diversified health care group, combining pharmaceuticals and medical technology after the spin-off of its consumer health activities into Kenvue in 2023. Johnson & Johnson investor presentation on strategy and capital allocation

At the same time, litigation remains a central theme in the equity story, particularly around talc-related claims and certain product liability cases. Analysts regularly assess the potential impact of such legal proceedings on the balance sheet and valuation, often comparing Johnson & Johnson with other large-cap health care peers such as Pfizer or Merck when it comes to risk profiles and cash flow resilience.

The product behind the stock

Johnson & Johnson now focuses on its pharmaceutical and medtech businesses, with key growth drivers including immunology therapies, oncology treatments and a broad portfolio of surgical and orthopedic devices. Blockbuster drugs and advanced medical devices help fund ongoing research and development and support the companys long-standing dividend policy.

Where the stock trades today

Johnson & Johnson shares trade on the New York Stock Exchange under the ticker JNJ; recent quotes place the stock in the upper double-digit US dollar range, reflecting its role as a large-cap defensive health care name in the S&P 500.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.